Luis R. Pizzolato-Cezar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis R. Pizzolato-Cezar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Andrey F. Z. Nascimento
Brazilian Synchrotron Light Source, Brazilian Centre for Research in Energy and Materials, Giuseppe Máximo Scolfaro 10000, 13083-100 Campinas SP, Brazil
1 shared publicationCaroline D. Lacerda
Department of Biochemistry, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, 05508-000 São Paulo SP, Brazil
1 shared publicationCleber W. Liria
Department of Biochemistry, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, 05508-000 São Paulo SP, Brazil
1 shared publication- German Gustavo Sgro
Universidade de São Paulo
1 shared publication - Maria Teresa Machini
University of São Paulo Avenida Prof. Lineu Prestes 748
1 shared publication Mario A. R. Pineda
Department of Biochemistry, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, 05508-000 São Paulo SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 13 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21665-21682
Development of a Potent and Functional In Vivo Peptide Competitive Inhibitor for the Toxin MazF
Cell growth regulation granted by toxin–antitoxin systems enables bacteria to fight phage infections, evade host immune defenses, and survive antibiotic treatment. In this work, a potent and specific peptide competitive inhibitor for the Escherichia coli toxin MazF was developed and named Small Antitoxin of MazF (SamF). Employing a set of N-acetylated and C-amidated synthetic peptides, biophysical methods, biochemistry, and molecular biology techniques, we demonstrated that SamF binds tightly and with high specificity to MazF in vitro and in vivo, blocking access to the substrate binding site. Coexpression of SamF with MazF in E. coli efficiently counteracted the metabolic downregulation imposed by the toxin and the formation of antibiotic persisters. Altogether, our data uncovered a new MazF druggable site and an excellent scaffold for the design of antimicrobials. SamF is also a promising tool to study MazF in vitro and its physiological function in bacteria.
- 13 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21665-21682
Open AccessDevelopment of a Potent and Functional In Vivo Peptide Competitive Inhibitor for the Toxin MazF
Cell growth regulation granted by toxin–antitoxin systems enables bacteria to fight phage infections, evade host immune defenses, and survive antibiotic treatment. In this work, a potent and specific peptide competitive inhibitor for the Escherichia coli toxin MazF was developed and named Small Antitoxin of MazF (SamF). Employing a set of N-acetylated and C-amidated synthetic peptides, biophysical methods, biochemistry, and molecular biology techniques, we demonstrated that SamF binds tightly and with high specificity to MazF in vitro and in vivo, blocking access to the substrate binding site. Coexpression of SamF with MazF in E. coli efficiently counteracted the metabolic downregulation imposed by the toxin and the formation of antibiotic persisters. Altogether, our data uncovered a new MazF druggable site and an excellent scaffold for the design of antimicrobials. SamF is also a promising tool to study MazF in vitro and its physiological function in bacteria.